There is an urgent requirement for new anti-infective compounds that can be used to prevent or treat bacterial pathogens. In particular, Gram-negative pathogens, which are most commonly associated with hospital-acquired infections, are of major concern. In this review, we cover recent developments in the screening and testing of new anti-infective compounds that interfere with aspects of bacterial pathogenicity. This so-called antivirulence approach is very different to traditional antibiotic development and testing. Moreover, antivirulence compounds vary considerably in their chemical structures, ranging from small compounds to large natural products. The challenge of understanding the precise mechanism of action of any such compound is also highlighted.
Keywords: biological screening; chemical biology; structure-based drug design; therapeutic target.
© 2015 John Wiley & Sons A/S.